score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Guideline		Guideline	Somatic Variant	KIT	Missense	p.K642E	0.6954	614.0	0.0	0.0		Putatively Actionable	Imatinib	KIT inhibition	Targeted therapy	KIT exon 11 and 13 variants (W557, V559, L576P, and K642E) appear to have high level of sensitivity to KIT inhibition.	National Comprehensive Cancer Network. Cutaneous Melanoma NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf. Accessed August 12, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf								Investigate Actionability	0.0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf	0				KIT p.K642E (Missense)	0.0	MEL-IPI_Pat58	MEL-IPI_Pat58-Tumor-SM-4DK2J	MEL-IPI_Pat58-Normal-SM-4NFVP
Putatively Actionable	Guideline			Copy Number	CDK4	Amplification				0.0	0.0		Putatively Actionable	Palbociclib	CDK4/6 inhibition	Targeted therapy	CDK4 amplification is characteristic of well-differentiated and dedifferentiated liposarcomas. Palbociclib shows activity in this context.	National Comprehensive Cancer Network. Soft Tissue Sarcoma NCCN Evidence Blocks (Version 1.2021). Accessed November 19th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf													0				CDK4 Amplification	1.0	MEL-IPI_Pat58	MEL-IPI_Pat58-Tumor-SM-4DK2J	
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.T411I	0.0476	147.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0.0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	0				BRAF p.T411I (Missense)	1.0	MEL-IPI_Pat58	MEL-IPI_Pat58-Tumor-SM-4DK2J	MEL-IPI_Pat58-Normal-SM-4NFVP
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.M942I	0.0305	164.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf						0				EGFR p.M942I (Missense)	1.0	MEL-IPI_Pat58	MEL-IPI_Pat58-Tumor-SM-4DK2J	MEL-IPI_Pat58-Normal-SM-4NFVP
Investigate Actionability	Guideline		Guideline	Somatic Variant	KIT	Missense	p.D816N	0.0454	1079.0	0.0	0.0		Investigate Actionability	Imatinib	KIT inhibition	Targeted therapy	KIT exon 11 and 13 variants (W557, V559, L576P, and K642E) appear to have high level of sensitivity to KIT inhibition.	National Comprehensive Cancer Network. Cutaneous Melanoma NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf. Accessed August 12, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf								Investigate Actionability	0.0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf	0				KIT p.D816N (Missense)	0.0	MEL-IPI_Pat58	MEL-IPI_Pat58-Tumor-SM-4DK2J	MEL-IPI_Pat58-Normal-SM-4NFVP
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.R453H	0.0242	248.0	6.6e-05	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475													0				ERBB3 p.R453H (Missense)		MEL-IPI_Pat58	MEL-IPI_Pat58-Tumor-SM-4DK2J	MEL-IPI_Pat58-Normal-SM-4NFVP
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.E555K	0.0476	147.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475													0				ERBB3 p.E555K (Missense)		MEL-IPI_Pat58	MEL-IPI_Pat58-Tumor-SM-4DK2J	MEL-IPI_Pat58-Normal-SM-4NFVP
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.V1018M	0.075	200.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475													0				ERBB2 p.V1018M (Missense)		MEL-IPI_Pat58	MEL-IPI_Pat58-Tumor-SM-4DK2J	MEL-IPI_Pat58-Normal-SM-4NFVP
Investigate Actionability	Clinical evidence			Mutational Burden	High Mutational Burden								Investigate Actionability	Ipilimumab	CTLA-4 inhibition	Immunotherapy	In a study of malignant melanoma using a discovery cohort of 25 patients and a validation cohort of 39 patients, a significantly higher muational burden was seen in patients with a long-term clinical benefit vs. patients with minimal or no benefit to ipilimumab treatment.	Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189-99.	https://doi.org/10.1056/NEJMoa1406498													0				 mutations per Mb		MEL-IPI_Pat58		
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.S323F	0.0165	423.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0.0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310	0				PIK3CA p.S323F (Missense)	1.0	MEL-IPI_Pat58	MEL-IPI_Pat58-Tumor-SM-4DK2J	MEL-IPI_Pat58-Normal-SM-4NFVP
Investigate Actionability	Preclinical			Somatic Variant	MPL	Missense	p.V368M	0.0347	202.0	0.0	0.0		Investigate Actionability	EXEL-8232	JAK2 inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to JAK2 inhibition. This variant was observed to suggest sensitivity to EXEL-8232 in vivo.	Wernig G, Kharas MG, Mullally A, et al. EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L. Leukemia. 2012;26(4):720-7.	https://doi.org/10.1038/leu.2011.261													0				MPL p.V368M (Missense)		MEL-IPI_Pat58	MEL-IPI_Pat58-Tumor-SM-4DK2J	MEL-IPI_Pat58-Normal-SM-4NFVP
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.A188T	0.0365	137.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007													0				ATM p.A188T (Missense)	1.0	MEL-IPI_Pat58	MEL-IPI_Pat58-Tumor-SM-4DK2J	MEL-IPI_Pat58-Normal-SM-4NFVP
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.G696R	0.0275	255.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007													0				ATM p.G696R (Missense)	1.0	MEL-IPI_Pat58	MEL-IPI_Pat58-Tumor-SM-4DK2J	MEL-IPI_Pat58-Normal-SM-4NFVP
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.P2353L	0.1314	137.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007													0				ATM p.P2353L (Missense)	1.0	MEL-IPI_Pat58	MEL-IPI_Pat58-Tumor-SM-4DK2J	MEL-IPI_Pat58-Normal-SM-4NFVP
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.E2366K	0.1327	113.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007													0				ATM p.E2366K (Missense)	1.0	MEL-IPI_Pat58	MEL-IPI_Pat58-Tumor-SM-4DK2J	MEL-IPI_Pat58-Normal-SM-4NFVP
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.G628R	0.0706	85.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220						0				AR p.G628R (Missense)		MEL-IPI_Pat58	MEL-IPI_Pat58-Tumor-SM-4DK2J	MEL-IPI_Pat58-Normal-SM-4NFVP
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.T7I	0.1379	203.0	8e-06	0.0																Investigate Actionability	1.0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				SF3B1 p.T7I (Missense)		MEL-IPI_Pat58	MEL-IPI_Pat58-Tumor-SM-4DK2J	MEL-IPI_Pat58-Normal-SM-4NFVP
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.S879N	0.0964	166.0	0.0	0.0																Investigate Actionability	0.0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828	0				BCOR p.S879N (Missense)		MEL-IPI_Pat58	MEL-IPI_Pat58-Tumor-SM-4DK2J	MEL-IPI_Pat58-Normal-SM-4NFVP
Investigate Actionability			Inferential	Aneuploidy	Whole genome doubling																						Investigate Actionability	0.0	WGD was associated with adverse survival pan-cancer in patients with advanced disease and in cancers with heterogeneous clinical outcomes, even following the development of metastasis.	Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers Nat Genet. 2018; 50(8):1189-1195.	https://doi.org/10.1038/s41588-018-0165-1	0						MEL-IPI_Pat58		
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.V932I	0.0948	496.0	8e-06	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677						0				BRCA1 p.V932I (Missense)	1.0	MEL-IPI_Pat58	MEL-IPI_Pat58-Tumor-SM-4DK2J	MEL-IPI_Pat58-Normal-SM-4NFVP
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK1	Missense	p.P188S	0.1213	239.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1.0	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287	0				CHEK1 p.P188S (Missense)	1.0	MEL-IPI_Pat58	MEL-IPI_Pat58-Tumor-SM-4DK2J	MEL-IPI_Pat58-Normal-SM-4NFVP
Investigate Actionability	Clinical evidence			Somatic Variant	ERRFI1	Missense	p.G27E	0.0578	502.0	8e-06	0.0		Investigate Actionability	Erlotinib	EGFR inhibition	Targeted therapy	Rapid disease regression was notd in a patient with a ERFFI1 p.E384X nonsense variant when treated with erlotinib.	Borad MJ, Champion MD, Egan JB, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014;10(2):e1004135.	https://doi.org/10.1371/journal.pgen.1004135													0				ERRFI1 p.G27E (Missense)	0.0	MEL-IPI_Pat58	MEL-IPI_Pat58-Tumor-SM-4DK2J	MEL-IPI_Pat58-Normal-SM-4NFVP
Investigate Actionability	Clinical evidence			Somatic Variant	MSH2	Missense	p.P507S	0.0251	199.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596													0				MSH2 p.P507S (Missense)		MEL-IPI_Pat58	MEL-IPI_Pat58-Tumor-SM-4DK2J	MEL-IPI_Pat58-Normal-SM-4NFVP
Investigate Actionability	Clinical evidence			Somatic Variant	MSH2	Splice Site	p.G587S	0.1512	205.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596													0				MSH2 p.G587S (Splice Site)		MEL-IPI_Pat58	MEL-IPI_Pat58-Tumor-SM-4DK2J	MEL-IPI_Pat58-Normal-SM-4NFVP
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Missense	p.P408L	0.0323	124.0	8e-06	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596													0				MSH6 p.P408L (Missense)		MEL-IPI_Pat58	MEL-IPI_Pat58-Tumor-SM-4DK2J	MEL-IPI_Pat58-Normal-SM-4NFVP
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Missense	p.G1134E	0.0175	286.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596													0				MSH6 p.G1134E (Missense)		MEL-IPI_Pat58	MEL-IPI_Pat58-Tumor-SM-4DK2J	MEL-IPI_Pat58-Normal-SM-4NFVP
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Missense	p.S1141F	0.0524	267.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596													0				MSH6 p.S1141F (Missense)		MEL-IPI_Pat58	MEL-IPI_Pat58-Tumor-SM-4DK2J	MEL-IPI_Pat58-Normal-SM-4NFVP
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Missense	p.G1157D	0.1452	124.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596													0				MSH6 p.G1157D (Missense)		MEL-IPI_Pat58	MEL-IPI_Pat58-Tumor-SM-4DK2J	MEL-IPI_Pat58-Normal-SM-4NFVP
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Missense	p.T1219I	0.0581	172.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596													0				MSH6 p.T1219I (Missense)		MEL-IPI_Pat58	MEL-IPI_Pat58-Tumor-SM-4DK2J	MEL-IPI_Pat58-Normal-SM-4NFVP
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Nonsense	p.Q1258*	0.0251	239.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596													0				MSH6 p.Q1258* (Nonsense)		MEL-IPI_Pat58	MEL-IPI_Pat58-Tumor-SM-4DK2J	MEL-IPI_Pat58-Normal-SM-4NFVP
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Splice Site		0.0806	62.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596													0				MSH6  (Splice Site)		MEL-IPI_Pat58	MEL-IPI_Pat58-Tumor-SM-4DK2J	MEL-IPI_Pat58-Normal-SM-4NFVP
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Missense	p.T326I	0.0184	381.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596													0				MLH3 p.T326I (Missense)		MEL-IPI_Pat58	MEL-IPI_Pat58-Tumor-SM-4DK2J	MEL-IPI_Pat58-Normal-SM-4NFVP
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.E2322K	0.0629	175.0	0.0	0.0																Investigate Actionability	0.0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				PRPF8 p.E2322K (Missense)		MEL-IPI_Pat58	MEL-IPI_Pat58-Tumor-SM-4DK2J	MEL-IPI_Pat58-Normal-SM-4NFVP
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Nonsense	p.Q2038*	0.0283	566.0	0.0	0.0																Investigate Actionability	0.0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				PRPF8 p.Q2038* (Nonsense)		MEL-IPI_Pat58	MEL-IPI_Pat58-Tumor-SM-4DK2J	MEL-IPI_Pat58-Normal-SM-4NFVP
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.S203F	0.0533	75.0	0.0	0.0																Investigate Actionability	0.0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				ASXL1 p.S203F (Missense)		MEL-IPI_Pat58	MEL-IPI_Pat58-Tumor-SM-4DK2J	MEL-IPI_Pat58-Normal-SM-4NFVP
Biologically Relevant				Somatic Variant	MTOR	Missense	p.E1427K	0.0752	266.0	0.0	0.0																					0				MTOR p.E1427K (Missense)		MEL-IPI_Pat58	MEL-IPI_Pat58-Tumor-SM-4DK2J	MEL-IPI_Pat58-Normal-SM-4NFVP
Biologically Relevant				Somatic Variant	ROS1	Nonsense	p.Q2175*	0.0606	99.0	8e-06	0.0																					0				ROS1 p.Q2175* (Nonsense)		MEL-IPI_Pat58	MEL-IPI_Pat58-Tumor-SM-4DK2J	MEL-IPI_Pat58-Normal-SM-4NFVP
Biologically Relevant				Somatic Variant	ROS1	Missense	p.A1907T	0.0231	260.0	0.0	0.0																					0				ROS1 p.A1907T (Missense)		MEL-IPI_Pat58	MEL-IPI_Pat58-Tumor-SM-4DK2J	MEL-IPI_Pat58-Normal-SM-4NFVP
Biologically Relevant				Somatic Variant	MDM2	Missense	p.G62D	0.0104	1055.0	0.0	0.0																					0				MDM2 p.G62D (Missense)		MEL-IPI_Pat58	MEL-IPI_Pat58-Tumor-SM-4DK2J	MEL-IPI_Pat58-Normal-SM-4NFVP
Biologically Relevant				Somatic Variant	POLE2	Missense	p.G373D	0.0305	164.0	0.0	0.0																					0				POLE2 p.G373D (Missense)		MEL-IPI_Pat58	MEL-IPI_Pat58-Tumor-SM-4DK2J	MEL-IPI_Pat58-Normal-SM-4NFVP
Biologically Relevant				Somatic Variant	NF1	Missense	p.G875D	0.1111	225.0	0.0	0.0																					0				NF1 p.G875D (Missense)		MEL-IPI_Pat58	MEL-IPI_Pat58-Tumor-SM-4DK2J	MEL-IPI_Pat58-Normal-SM-4NFVP
Biologically Relevant				Somatic Variant	NF1	Splice Site		0.0491	387.0	0.0	0.0																					0				NF1  (Splice Site)		MEL-IPI_Pat58	MEL-IPI_Pat58-Tumor-SM-4DK2J	MEL-IPI_Pat58-Normal-SM-4NFVP
Biologically Relevant				Somatic Variant	IL12RB1	Missense	p.D145N	0.0392	102.0	0.0	0.0																					0				IL12RB1 p.D145N (Missense)		MEL-IPI_Pat58	MEL-IPI_Pat58-Tumor-SM-4DK2J	MEL-IPI_Pat58-Normal-SM-4NFVP
Biologically Relevant				Somatic Variant	TPX2	Missense	p.S174N	0.1145	262.0	0.0	0.0																					0				TPX2 p.S174N (Missense)		MEL-IPI_Pat58	MEL-IPI_Pat58-Tumor-SM-4DK2J	MEL-IPI_Pat58-Normal-SM-4NFVP
Biologically Relevant				Somatic Variant	LIMK2	Missense	p.P569L	0.0833	120.0	0.0	0.0																					0				LIMK2 p.P569L (Missense)		MEL-IPI_Pat58	MEL-IPI_Pat58-Tumor-SM-4DK2J	MEL-IPI_Pat58-Normal-SM-4NFVP
Biologically Relevant				Copy Number	RET	Deletion				0.0	0.0																					0				RET Deletion		MEL-IPI_Pat58	MEL-IPI_Pat58-Tumor-SM-4DK2J	
Biologically Relevant				Copy Number	LIMK2	Deletion				0.0	0.0																					0				LIMK2 Deletion		MEL-IPI_Pat58	MEL-IPI_Pat58-Tumor-SM-4DK2J	
Biologically Relevant				Copy Number	TSC2	Deletion				0.0	0.0																					0				TSC2 Deletion		MEL-IPI_Pat58	MEL-IPI_Pat58-Tumor-SM-4DK2J	
Biologically Relevant				Microsatellite Stability	Supporting variants		MSH2 p.G587S (Splice Site), MSH6 p.Q1258* (Nonsense), nan, MSH3 p.PPA66del (Deletion)																									0				Supporting variants: MSH2 p.G587S (Splice Site), MSH6 p.Q1258* (Nonsense), nan, MSH3 p.PPA66del (Deletion)		MEL-IPI_Pat58		
Biologically Relevant				Mutational Signature	COSMIC Signature 11	version 2	0.976																									0				COSMIC Signature (version 2) 11 (98%)		MEL-IPI_Pat58		
